Macitentan for the treatment of pulmonary arterial hypertension

Bibliography

• Badesch DB, Raskob GE, Eliott G, et al. Pulmonary Artery Hypertension: baseline Characteristics From the REVEAL registry. Chest 2010;137(2):376-87
   PubMedGoogle Scholar
• Humbert M, Sitbon O, Simonneau G. Treatment of Pulmonary Arterial Hypertension. N Eng J Med 2004;351:1425-36
   PubMed Web of Science ®Google Scholar
• Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903. Erratum, N Engl J Med 2002;346:1258
   PubMed Web of Science ®Google Scholar
• Galie N, Olschewski H, Oudiz RJ. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2. Circulation 2008;117:3010-19
   PubMed Web of Science ®Google Scholar
• Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148-57. Erratum, N Engl J Med 2006;354:2400-1
   PubMed Web of Science ®Google Scholar
• Galie N, Brundage B, Ghofrani A, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009;119:2894-903. Erratum, Circulation 2011;124(10):e279
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, Galiè N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013;369:330-40
   PubMed Web of Science ®Google Scholar
• Barst RJ, Rubin LJ, Long WA, et al. A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary Hypertension. N Engl J Med 1996;334:296-301
   PubMed Web of Science ®Google Scholar
• Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347:322-9
   PubMed Web of Science ®Google Scholar
• Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analog, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:800-4
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol 2010;55:1915-22
   PubMed Web of Science ®Google Scholar
• Benza RL, Miller DP, Barst RJ, et al. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from REVEAL. Chest 2012;142:448-56
   PubMed Web of Science ®Google Scholar
• Ortega Mateo, A, de Artiñano, A. Highlights on endothelins: a review. Pharmacol Res 1997;36:339-51
   Web of Science ®Google Scholar
• Lüscher TF, Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation 2000;102:2434-40
   PubMed Web of Science ®Google Scholar
• Pollock DM. Endothelin, angiotensin, and oxidative stress in hypertension. Hypertension 2005;45:477-80
   PubMed Web of Science ®Google Scholar
• Dupuis J, Stewart D, Cernacek P, Gosselin G. Human pulmonary circulation is an important site for both clearance and production ofendothelin-1. Circulation 1996;94:1578-84
   PubMed Web of Science ®Google Scholar
• Fukuroda T, Fujikawa T, Ozaki S, et al. Clearance of circulating endothelin-1 by ETB receptors in rats. Biochem Biophys Res Commun 1994;199:146114
   Google Scholar
• Hirata Y, Emori T, Eguchi S, et al. Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. J Clin Invest 1993;91:1367-73
   PubMed Web of Science ®Google Scholar
• Dupuis J, Hoeper M. Endothelin receptor antagonists in pulmonary arterial hypertension. Eur Respir J 2008;31:407-15
   PubMed Web of Science ®Google Scholar
• Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993;328:1732-9
   PubMed Web of Science ®Google Scholar
• Rubens C, Ewert R, Halank M, et al. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest J 2001;120:1562-9
   PubMed Web of Science ®Google Scholar
• Yu J, Taylor L, Wilson J, et al. Altered expression and signal transduction of endothelin-1 receptors in heritable and idiopathic pulmonary arterial hypertension. J Cell Physiol 2013;228:322-9
   Google Scholar
• Juergens U, Racké K, Uen S, et al. Inflammatory responses after endothelin B (ETB) receptor activation in human monocytes: new evidence for beneficial anti-inflammatory potency of ETB-receptor antagonism. Pulm Pharmacol Ther 2008;21:533-9
   Google Scholar
• Dupuis J, Prié S. The ET(A)-receptor antagonist LU 135252 prevents the progression of established pulmonary hypertension induced by monocrotaline in rats. J Cardiovasc Pharmacol Ther 1999;4:33-9
   Google Scholar
• Prié S, Leung T, Cernacek P, et al. The orally active ET(A) receptor antagonist (+)-(S)-2-(4,6-dimethoxy-pyrimidin-2-yloxy)-3-methoxy-3,3-diphe nyl-propionic acid (LU 135252) prevents the development of pulmonary hypertension and endothelial metabolic dysfunction in monocrotaline treated rats. J Pharmacol Exp Ther 1997;282:1312-18
   PubMed Web of Science ®Google Scholar
• Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study. Lancet 2001;358:1119-23
   PubMed Web of Science ®Google Scholar
• Bolli MH, Boss C, Binkert C, et al. The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N’-propylsulfamide (macitentan), an orally active, potent, dual endothelin receptor antagonist. J Med Chem 2012;55:7849-61
   PubMed Web of Science ®Google Scholar
• Iglarz M, Binkert C, Morrison K, et al. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther 2008;327:736-45
   PubMed Web of Science ®Google Scholar
• Bruderer S, Hopfgartner G, Seiberling M, et al. Absorption, distribution, metabolism, and excretion of macitentan, a dual endothelin receptor antagonist, in humans. Xenobiotica Fate Foreign Compd Biol Syst 2012b;42:901-10
   PubMed Web of Science ®Google Scholar
• Bruderer S, Marjason J, Sidharta P, Dingemanse J. Pharmacokinetics of macitentan in Caucasian and Japanese subjects: the influence of ethnicity and sex. Pharmacology 2013;91:331-8
   PubMed Web of Science ®Google Scholar
• Atsmon J, Dingemanse J, Shaikevich D, et al. Investigation of the effects of ketoconazole on the pharmacokinetics of macitentan, a novel dual endothelin receptor antagonist, in healthy subjects. Clin Pharmacokinet 2013;52:685-92
   PubMed Web of Science ®Google Scholar
• Sidharta P, van Giersbergen P, Halabi A, Dingemanse J. Macitentan: entry-into-humans study with a new endothelin receptor antagonist. Eur J Clin Pharmacol 2011;67:977-84
   PubMed Web of Science ®Google Scholar
• Sidharta P, Lindegger N, van Giersbergen P, Dingemanse J. Single-dose pharmacokinetics, safety, and tolerability of macitentan, a new endothelin receptor antagonist, in subjects with mild, moderate or severe hepatic impairment. Chest 2012;142:826A
   Google Scholar
• Gatfield J, Mueller Grandjean C, Sasse T, et al. Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells. PLoS One 2012; doi: 10.1371/journal.pone.0047662
   Google Scholar
• Pulido T, Adzerikho I, Channick R, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013;369:809-18
   PubMed Web of Science ®Google Scholar
• Ben-Yehuda O, Pizzuti D, Brown A. Long-term hepatic safety of ambrisentan in patients with pulmonary arterial hypertension. J Am Coll Cardiol 2012;60(1):80-1
   PubMed Web of Science ®Google Scholar